The treatment of inflammatory bowel disease (IBD) frequently includes the
use of immunosuppressive medications, which may increase patients' susceptibility to
infections depending on the specific therapies administered. As the COVID-19
outbreak progressed into a global pandemic, multiple centers worldwide expressed
concerns that immunocompromised individuals, including those with IBD, could be
at heightened risk for acquiring SARS-CoV-2 infection or developing severe
respiratory illness (13).